Literature DB >> 23828788

Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model.

Yuki Tomozawa1, Norihisa Nitta, Shinji Ohta, Hideji Otani, Shobu Watanabe, Akinaga Sonoda, Keiko Tsuchiya, Ayumi Nitta-Seko, Masashi Takahashi, Kiyoshi Murata.   

Abstract

OBJECTIVE: To evaluate the antitumor effects of miriplatin-lipidol suspension and emulsion.
MATERIALS AND METHODS: Fifty rabbits with VX2 liver tumors were randomly assigned to ten groups. Then, we prepared four types of mixtures: a suspension of lipiodol and miriplatin (ML), an emulsion of miriplatin dissolved with lipiodol and contrast medium (MLC) or saline (MLS), and saline alone (S). Ratios between lipiodol and contrast medium/saline volumes were 1:1/4, 1:1/2, 1:1, and 1:2 respectively. We used the same dose of miriplatin (2 mg/kg) and lipiodol (0.1 ml/kg) in each emulsion and suspension group. After intra-arterial infusion, the tumor growth rate was calculated, and sequential change of the plasma platinum concentration, the platinum concentration in the tumor and in surrounding normal liver tissue was also measured.
RESULTS: Among the ten groups, the tumor growth rate was lower in MLC and MLS groups, and the difference between tumor treated with MLS emulsion (ratio 1:1/2) and ML suspension was significant (p = 0.02). The platinum concentration in the normal liver tissue was lower in MLS and MLC groups than in the ML group, and that in the tumor was higher in the MLS and MLC emulsion (ratio 1:1/2) groups.
CONCLUSION: We suggest that miriplatin-lipiodol emulsion may be more effective than suspension.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23828788     DOI: 10.1007/s11604-013-0231-7

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  30 in total

1.  Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

Authors:  Norihiro Imai; Kenji Ikeda; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  Jpn J Clin Oncol       Date:  2011-12-30       Impact factor: 3.019

2.  Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE).

Authors:  Y Shimamura; P Gunvèn; Y Takenaka; H Shimizu; Y Shima; H Akimoto; K Arima; A Takahashi; T Kitaya; T Matsuyama
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

3.  Combined tumor therapy by using radiofrequency ablation and 5-FU-laden polymer implants: evaluation in rats and rabbits.

Authors:  John R Haaga; Agata A Exner; Yadong Wang; Nicholas T Stowe; Peter J Tarcha
Journal:  Radiology       Date:  2005-10-19       Impact factor: 11.105

4.  Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma.

Authors:  Kazuhiro Kasai; Akira Ushio; Kei Sawara; Yasuhiro Miyamoto; Yukiho Kasai; Kanta Oikawa; Hidekatsu Kuroda; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

5.  Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study.

Authors:  T de Baere; X Zhang; B Aubert; G Harry; C Lagrange; J Ropers; J Dufaux; J Lumbroso; P Rougier; M Ducreux; A Roche
Journal:  Radiology       Date:  1996-12       Impact factor: 11.105

Review 6.  Hepatocellular carcinoma: current management and recent advances.

Authors:  Wan-Yee Lau; Eric C H Lai
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2008-06

7.  Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats.

Authors:  Mitsuharu Hanada; Akemi Baba; Yasuyuki Tsutsumishita; Toshihiro Noguchi; Takashi Yamaoka
Journal:  Cancer Sci       Date:  2008-11-24       Impact factor: 6.716

8.  Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma.

Authors:  Takuji Okusaka; Shuichi Okada; Hideki Ueno; Masafumi Ikeda; Ryoko Iwata; Hiroyoshi Furukawa; Kenichi Takayasu; Noriyuki Moriyama; Tosiya Sato; Keiko Sato
Journal:  Oncology       Date:  2002       Impact factor: 2.935

9.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

10.  Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol.

Authors:  S Fujiyama; J Shibata; S Maeda; M Tanaka; S Noumaru; K Sato; K Tomita
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.